King Pharmaceuticals has launched a tablet formulation of Altace (ramipril). The tablets will be available in 1.25mg, 2.5mg, 5mg, and 10mg dosage strengths and are indicated for the treatment of hypertension; CHF in stabilized patients after MI; to reduce mortality, hospitalizations and progression to severe/resistant heat failure; and to reduce risk of MI, stroke, or death from cardiovascular causes in high-risk patients ≥55 years old.

For more information call (888) 840-5370 or visit